Market Place
Sourcing Support
Voyager Selects Tau Silencing Gene Therapy For Alzheimer’s Disease
20 Nov 2024 //
GLOBENEWSWIRE
Voyager Reports Q3 2024 Financial & Operating Results
12 Nov 2024 //
GLOBENEWSWIRE
Voyager Therapeutics to Present at Multiple Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Announces Q3 2024 Conference Call & Webcast
05 Nov 2024 //
GLOBENEWSWIRE
Voyager And Neurocrine Select Third Gene Therapy Candidate
16 Sep 2024 //
GLOBENEWSWIRE
Voyager Enters License For Next-Generation Capsid
05 Sep 2024 //
GLOBENEWSWIRE
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635
29 Aug 2024 //
GLOBENEWSWIRE
Voyager Therapeutics To Present At Canaccord Genuity Growth Conference
07 Aug 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
06 Aug 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
30 Jul 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Rule
23 Jul 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Announces Inducement Grants Under NASDAQ Rule
09 Jul 2024 //
GLOBENEWSWIRE
Voyager Therapeutics To Present At Multiple Investor Conferences
13 Jun 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
13 May 2024 //
GLOBENEWSWIRE
Voyager TRACER Capsids, CNS Gene Therapy Data At ASGCT
08 May 2024 //
GLOBENEWSWIRE
Voyager Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 Mar 2024 //
GLOBENEWSWIRE
Voyager Therapeutics Announces Pricing of Public Offering
04 Jan 2024 //
PRESS RELEASE
Voyager Enters Agreement and Strategic Collaboration with Novartis
02 Jan 2024 //
PRESS RELEASE
Novartis, Voyager launch $100M gene therapy mission
02 Jan 2024 //
FIERCE BIOTECH
Voyager asset lands on planet Alexion after Pfizer handoff
06 Nov 2023 //
FIERCE BIOTECH
Voyager Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Sep 2023 //
GLOBENEWSWIRE
Voyager Announces Appointment of Beth Shafer as Chief Business Officer
07 Aug 2023 //
GLOBENEWSWIRE
Voyager adds anti-amyloid gene therapy to Alzheimer`s pipeline
04 Aug 2023 //
FIERCE BIOTECH
Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference
02 Aug 2023 //
GLOBENEWSWIRE
Will VGX Thrive Despite Crypto Lender’s Bankruptcy, SEC Claims?
21 Jun 2023 //
CCN
Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?
21 Jun 2023 //
FINANCE YAHOO
Voyager`s Stock`s On An Uptrend: Are Strong Financials Guiding The Market?
25 May 2023 //
FINANCE YAHOO
Voyager Life "now capable of dealing with multinational customers"
24 May 2023 //
FINANCE YAHOO
Voyager Presents Robust, Results from Preclinical Studies of IV-Delivered
18 May 2023 //
GLOBENEWSWIRE
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results
09 May 2023 //
GLOBENEWSWIRE
George Scangos joins Voyager board in reunion with Biogen colleague Al Sandrock
09 May 2023 //
ENDPTS
Voyager Therapeutics Announces Multiple Data Presentations at Annual Meeting
02 May 2023 //
PRESS RELEASE
Voyager Presents Data Supporting Tau Antibody Program for Alzheimer`s Disease
28 Mar 2023 //
GLOBENEWSWIRE
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial
07 Mar 2023 //
GLOBENEWSWIRE
Voyager to Receive $25M Payment for License of AAV Capsids
06 Mar 2023 //
GLOBENEWSWIRE
Novartis ready to head for deep space with Voyager
06 Mar 2023 //
FIERCE BIOTECH
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO & Aspirin
05 Mar 2023 //
PR NEWSWIRE
Voyager Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast
28 Feb 2023 //
GLOBENEWSWIRE
Voyager Therapeutics to Participate in Upcoming Investor Conferences
09 Feb 2023 //
GLOBENEWSWIRE
Voyager Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 Jan 2023 //
GLOBENEWSWIRE
Voyager nets up to $1.7 billion in Neurocrine gene therapy pact
10 Jan 2023 //
GLOBENEWSWIRE
Voyager Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
14 Dec 2022 //
GLOBENEWSWIRE
Voyager Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Nov 2022 //
GLOBENEWSWIRE
Touchlight signs license agreement with Voyager for use of DNA technology
25 Nov 2022 //
PRESS RELEASE
Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results
08 Nov 2022 //
GLOBENEWSWIRE
Voyager Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Oct 2022 //
GLOBENEWSWIRE
Voyager Therapeutics Presents Data Characterizing a Novel CNS Receptor
11 Oct 2022 //
GLOBENEWSWIRE
Pfizer pulls trigger on Voyager gene therapy capsid deal
05 Oct 2022 //
FIERCEBIOTECH
Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid
04 Oct 2022 //
GLOBENEWSWIRE
Voyager Announces Data Presentations at the 29th Annual Congress of the ESGCT
03 Oct 2022 //
GLOBENEWSWIRE
Voyager Therapeutics to Participate in Upcoming Investor Conferences
27 Sep 2022 //
GLOBENEWSWIRE
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
22 Sep 2022 //
GLOBENEWSWIRE
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO
07 Sep 2022 //
GLOBENEWSWIRE
As it rebuilds, Voyager casts clinical sails towards CNS
05 Aug 2022 //
FIERCEBIOTECH
Voyager Therapeutics Reports Second Quarter 2022 Financial and Operating Results
04 Aug 2022 //
GLOBENEWSWIRE
Voyager Presents New Data Demonstrating Novel Candidate Therapeutic Abs
03 Aug 2022 //
GLOBENEWSWIRE
Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
02 Aug 2022 //
GLOBENEWSWIRE
Voyager Tx Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
28 Jul 2022 //
GLOBENEWSWIRE
